Our studies show that blocking TGF‐β activity with an anti‐TGF‐β antibody in the dominant OI mouse model leads to profound efficacy in the lumbar and femoral bones measured via imaging and biomechanical testing. This evidence concerns the gene TGFB1 and osteogenesis imperfecta.